Yongin-si, South Korea

Sang-ho Ma


Average Co-Inventor Count = 12.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in Oncology: The Contributions of Inventor Sang-ho Ma

Introduction

Sang-ho Ma, based in Yongin-si, South Korea, is a notable inventor recognized for his significant contributions to the field of oncology through innovative pharmaceutical compositions. With a total of three patents to his name, his work primarily focuses on developing compounds that target critical kinases involved in cancer and inflammation.

Latest Patents

Sang-ho Ma's latest patents include groundbreaking research on pyrazole derivatives which act as inhibitors for TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon), and TBK1 (TANK-binding kinase 1). These compounds demonstrate promising potential as anticancer agents, offering hope for patients suffering from various cancers such as colorectal, breast, kidney, and lung cancers, among others. Additionally, he has developed 7-azaindole and 4,7-diazaindole derivatives, which also inhibit IKKε and TBK1, underscoring their utility in both cancer treatment and chronic inflammation therapies.

Career Highlights

Currently, Sang-ho Ma is affiliated with Green Cross Corporation, a leading company in the biopharmaceutical sector. His innovative approaches have been instrumental in advancing the understanding of targeted cancer therapies, making significant impacts in the medical community.

Collaborations

Throughout his career, Sang-ho Ma has collaborated with esteemed colleagues such as Soongyu Choi and Kisoo Park. Together, they work on developing new therapeutic strategies aimed at combating cancer and chronic inflammatory diseases, highlighting the importance of teamwork in achieving scientific breakthroughs.

Conclusion

Sang-ho Ma's contributions to medical research through his patents not only reflect his dedication to innovation but also offer tangible benefits for cancer treatment and chronic inflammation management. His work at Green Cross Corporation, coupled with strategic collaborations, sets a remarkable example of how dedicated inventors can drive progress in the pharmaceutical industry and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…